ArticleProceedings of the National Academy of Sciences of the United States of America2017
Rifamycin action on RNA polymerase in antibiotic-tolerant
Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 93 citations in OpenAlex.
- MakingCell insight · 2026Review
- Desiccation promotes DNA damage and rifampin resistance in Mycobacterium tuberculosis.Nature microbiology · 2026Article
- Reactive oxygen detoxification contributes toeLife · 2026Article
- Beyond Urease: New Potential Enzymatic Targets inACS omega · 2026Review
- Reactive Oxygen Detoxification Contributes tobioRxiv : the preprint server for biology · 2025Article
- Trehalose catalytic shift inherently enhances phenotypic heterogeneity and multidrug resistance in Mycobacterium tuberculosis.Nature communications · 2025Article
- Drug-induced differential culturability in diverse strains of Mycobacterium tuberculosis.Scientific reports · 2025Article
- The impact of physiological state and environmental stress on bacterial load estimation methodologies for Mycobacterium tuberculosis.Scientific reports · 2024Article
- Nitric oxide induces the distinct invisibility phenotype of Mycobacterium tuberculosis.Communications biology · 2024Article
- Article
- A Bedaquiline, Pyrazinamide, Levofloxacin, Linezolid, and Clofazimine Second-line Regimen for Tuberculosis Displays Similar Early Bactericidal Activity as the Standard Rifampin-Based First-line Regimen.The Journal of infectious diseases · 2024Article
- High variance in quantification ofAntimicrobial agents and chemotherapy · 2024Article
- Clinical Strains ofPathogens (Basel, Switzerland) · 2024Article
- Article
- Article
- A tRNA modification ineLife · 2023Article
- Culture-negative TB: clinical characteristics, risk factors and treatment outcomes.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
- A tRNA modification inbioRxiv : the preprint server for biology · 2023Article
- Eradication of Drug-TolerantMicroorganisms · 2023Review
- High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: Evidence for heteroresistance.PLoS computational biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.